Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
CONCLUSION: Desvenlafaxine 20 to 50 mg/d was generally safe and well tolerated with no new safety signals identified in children and adolescents with MDD who received up to 6 months of treatment in these studies. Patients maintained the reduction in severity of depressive symptoms observed in all treatment groups at the end of the lead-in study.
PMID: 30419989 [PubMed - as supplied by publisher]
Source: CNS Spectrums - Category: Neurology Authors: Atkinson S, Thurman L, Ramaker S, Buckley G, Jones SR, England R, Wajsbrot D Tags: CNS Spectr Source Type: research
More News: Children | Depression | Electrocardiogram | Laboratory Medicine | Pristiq | Psychiatry | Study | Suicide